Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 110, Issue , 2013, Pages 74-80

  Miao, Jing ^a   Du, Yong Zhong ^b   Yuan, Hong ^b   Zhang, Xing Guo ^a   Hu, Fu Qiang ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Cytotoxicity; Doxorubicin; Multi drug resistance; Paclitaxel; Solid lipid nanoparticles

Indexed keywords

DOXORUBICIN; DRUG CONCENTRATION; GROWTH INHIBITION; MULTIDRUG RESISTANCE; OVARIAN CANCER CELLS; PACLITAXEL; SOLID LIPID NANOPARTICLE (SLN); SOLVENT DIFFUSION METHODS;

CELLS; CYTOLOGY; CYTOTOXICITY; NANOPARTICLES;

PHARMACODYNAMICS;

DOXORUBICIN; PACLITAXEL; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESISTANCE REVERSAL ACTIVITY; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; WILD TYPE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPIDS; MCF-7 CELLS; NANOPARTICLES; NEOPLASMS; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84878380072     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.03.037     Document Type: Article

References (18)

1. Krishna R., Mayer L.D. Eur. J. Pharm. Sci. 2000, 11:265.
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Annu. Rev. Pharmacol. Toxicol. 1999, 39:361.
3. Zhou C.G., Shen P., Cheng Y.Y. Biochim. Biophys. Acta 2007, 7(2007):1011.
4. Antonella M., Roberta C., Claudia B., Ludovica G. Int. J. Pharm. 2000, 210:61.
5. Mahesh D.C., Yogesh P., Jayanth P. Int. J. Pharm. 2006, 320:150.
6. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Clin. Cancer Res. 2000, 6:1949.
7. Müller R.H., Maaßen S., Weyhers H. Int. J. Pharm. 1996, 138:85.
8. Yang S.C., Zhu J.B., Lu Y., Liang B.W., Yang C.Z. Pharm. Res. 1999, 16:751.
9. Maaßen S., Schwarz C., Mehnert W. Proc. Int. Symp. Control. Release Bioact. Mater. 1993, 20:490.
10. Hu F.Q., Yuan H., Zhang H.H., Fang M. Int. J. Pharm. 2002, 239:121.
11. Yuan H., Chen J., Du Y.Z., Hu F.Q., Zeng S. Colloids Surf. B-Biointerfaces 2007, 58:157.
12. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., Zeng S. Int. J. Pharm. 2008, 348:137.
13. Lee E.S., Na K., Bae Y.H. J. Control. Release 2005, 103:405.
14. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., Zeng S. Int. J. Pharm. 2006, 314:83.
15. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., Zeng S. Colloids Surf. B-Biointerface 2005, 45:167.
16. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., Chen C., Chen X., Choo E., Cianfrogna J., et al. Drug Metab. Dispos. 2005, 33:165.
17. Serpea L., Catalanob M.G., Cavalli R. Eur. J. Pharm. Biopharm. 2004, 58:673.
18. Barraud L., Merle P., Soma E. J. Hepatol. 2005, 42:736.